Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 3/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11180181 | 0.97 | SIGMAR1 (0.62) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL19478721 | 0.97 | SIGMAR1 (0.62) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL9242693 | 0.95 | SIGMAR1 (0.67) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL11489807 | 0.94 | — | — | |
| SCHEMBL22510552 | 0.92 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL22700174 | 0.89 | SIGMAR1 (0.58) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL25020596 | 0.89 | SIGMAR1 (0.58) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL324846 | 0.85 | SIGMAR1 (0.65) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL10643742 | 0.82 | SIGMAR1 (0.62) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL9190697 | 0.82 | SIGMAR1 (0.70) | SIGMAR1CYP1A2EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135501-A1 | MONO-SUBSTITUTED CYCLOPENTADIENES AND METAL CYCLOPENTADIENYL COMPLEXES AND SYNTHESIS METHODS THEREOF | LARI LIQUIDE SOC ANOYME POUR IETUDE ET IEXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2022-05-05 | — | — | US | disclosed |
| US-20220048837-A1 | MONO-SUBSTITUTED CYCLOPENTADIENES AND METAL CYCLOPENTADIENYL COMPLEXES AND SYNTHESIS METHODS THEREOF | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude (FR) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135501-A1 | MONO-SUBSTITUTED CYCLOPENTADIENES AND METAL CYCLOPENTADIENYL COMPLEXES AND SYNTHESIS METHODS THEREOF | NR1H4, NR1H3, NR1H2 | SIGMAR1 657/4885CYP1A2 824/4885EPHX1 3742/4885 |
| US-20220048837-A1 | MONO-SUBSTITUTED CYCLOPENTADIENES AND METAL CYCLOPENTADIENYL COMPLEXES AND SYNTHESIS METHODS THEREOF | SOD1, SOD3, CAD | SIGMAR1 3119/4885CYP1A2 145/4885EPHX1 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.